Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Microemissive Displays Group LSE:MED London Ordinary Share GB00BN791Q39 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 7.60p 7.20p 8.00p 7.60p 7.60p 7.60p 0 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 4.2 -5.5 -11.7 - 11.90

Microemissive Displays Share Discussion Threads

Showing 826 to 845 of 850 messages
Chat Pages: 34  33  32  31  30  29  28  27  26  25  24  23  Older
Another Non-Regulatory RNS today Medaphor Group PLC AI database exceeds 1 million images 27 November 2018 MedaPhor Group plc ("MedaPhor" or the "Company") MedaPhor's AI obstetric image database exceeds 1 million images MedaPhor, the intelligent ultrasound software and simulation company, is pleased to announce that its database used for training its artificial intelligence (AI) products now exceeds 1 million obstetric ultrasound images. Large image libraries are a prerequisite to creating AI solutions. These images have helped MedaPhor to develop its ScanNav(R) AI-based clinical software for ultrasound professionals. The one million mark is a significant milestone for the Company, as it will enable it to build on its ScanNav software for the global obstetric ultrasound market. MedaPhor's ScanNav intelligent ultrasound technology, which uses AI algorithms and deep learning techniques to automatically assess ultrasound images, is currently being piloted in UK hospitals to support sonographers carrying out the 20 week anatomy scan. ScanNav assists sonographers to ensure that the images they are taking conform to the UK Fetal Anomaly Screening Programme (FASP) protocol. In future, the software will also be capable of automatically recording required images during the ultrasound scan. Continued.........
RNS Non-Regulatory today. Medaphor Group PLC MedaPhor commences clinical trial for AnatomyGuide 23/11/2018 3:56pm RNS Non-Regulatory MedaPhor commences clinical trial for AnatomyGuide MedaPhor (AIM:MED), the intelligent ultrasound software and simulation company, announces it is commencing a clinical trial within the Aneurin Bevan University Health Board to capture data for its AnatomyGuide artificial intelligence (AI) software for ultrasound-guided anaesthetic procedures such as peripheral nerve blocks. Increasingly, ultrasound-guided peripheral nerve blocks are being used as a safer and more cost-effective alternative to general anaesthesia but not all anaesthetists have the specialist knowledge of ultrasound anatomy to perform them. AnatomyGuide provides software support and guidance to aid less experienced clinicians during the procedure. Using deep-learning techniques on a data set of thousands of real-patient images, the technology is 'taught' to recognise key anatomical structures. Then, by highlighting these structures in real-time during an ultrasound-guided nerve block procedure, AnatomyGuide's AI makes it easier for clinicians to accurately target the nerve. The clinical data from the Aneurin Bevan clinical trial is expected to complete the required data set. Through the adoption of AnatomyGuide, it is hoped that hospitals will be able to increase the number of ultrasound-guided nerve blocks that they can perform. Principal Investigator and consultant anaesthetist, Dr David Burckett-St.Laurent, said: "AnatomyGuide will help tip the balance of safety and confidence in favour of performing regional anaesthesia. I feel privileged to work with a Welsh company that is leading the world in developing AI-based ultrasound software. Our aim is to make a real clinical difference to patients by increasing the availability of regional anaesthesia through cutting edge technology. It is very exciting." AnatomyGuide is being developed as part of an Innovate UK project funded within the government's AI and data grand challenge. Nicholas Sleep, CTO at MedaPhor, commented: "AnatomyGuide shows how strategic government investment can catalyse an innovative technology that we hope will make a real difference to NHS patient care. The team in Cardiff are excited to be working with Innovate UK in developing AI technology that has real-world applications and we look forward to completing the clinical trials with David and the Aneurin Bevan University Health Board."
Another nice sale - UK sales building
Look at 29 May RNS in header above
what specific annoucement i dont visit this board oftern 18 BT
That’s a big leap, presumably on the back of yesterday’s announcement
In respect of each director's share options set out above, one third of the above share options will vest once the closing mid-market price of the Company's Ordinary Shares reaches an average of least 25p per share for a continuous period of 20 business days; one third of the share options will vest once the closing mid-market price of the Company's Ordinary Shares reaches an average of at least 37.5p per share for a continuous period of 20 business days and the final third of the share options will vest once the closing mid-market price of the Company's Ordinary Shares reaches an average of at least 50p per share for a continuous period of 20 business days. Any unexercised options will lapse on 29 May 2028.
Exercise price 11.25p for options per rns
Great RNS with Share Options awarded for a significant increase in share price
Commenting, Nicholas Sleep, Chief Technology Officer of MedaPhor, said: "We are delighted to have been awarded the Innovate UK grant, which will not only cover the majority of our development costs, but also provides strong external validation of our technology and market need. NeedleGuide(TM) has enormous potential to improve patient outcomes, reducing the time and cost of these difficult procedures. We believe that this technology could reduce the cost of needling to all hospitals and have significant export potential as a new and world-leading digital health technology."
Seem to have picked up a shareholding via the Parkwalk EIS Funds in the placing. Interesting company and acquisition and now need to research ...
Disappointing half year report unfortunately. Burning cash at a high rate and only sufficient for a few months more
nothing comes up on google- gervais williams is supposed to be invested but i am not used at such a paucity of info even on this board!
EMED Mining (LON:EMED) this morning unveiled some early encouraging scout results from the Banska Stiavnica precious metals field, some 35 kilometres south-west of its Biely Vrch project in central Slovakia.
All MED Scotland employees made redundant. A Scottish company now only has a German base. Rumours of Chinese interest in the company. Fraunhofer Institute also showing a little interest allegedly.
Sounds like it may go private with no pay back for share holders. Why should a company be allowed to get suspended if it is still operating? If it is still employing staff so it should still be trading, OK maybe at an even lower market cap.
hyper al
From the Scotsman this morning MED calls in administrators – and more technology failures feared A SCOTS company credited with developing the world's smallest television screen has become the latest victim of the global economic crisis, prompting fears that there could be a wave of business failures in the technology sector. MicroEmissive Displays is to appoint an administrator after failing to find funding to support its pioneering business. The Edinburgh-based firm, led by chief executive Bill Miller, said yesterday it had been hit by the "severe slowdown" in the demand for consumer electronics – and had been unable to borrow enough cash to survive . MED, which has about 50 staff – evenly split between its operations in Scotland and Dresden, Germany – is continuing to trade and has not yet made any staffing cuts as a result of yesterday's announcement. In June it said it was to cut five jobs after issuing a profit warning, saying monthly profitability would be delayed until 2009. Last night technology entrepreneur and investor Ian Ritchie said he believed that , following the collapse, other struggling firms in the sector could suffer a similar fate. He said: "I think it is very likely that a lot more technology companies will fold, like in the dot com bust in 2001, when a lot of good companies were wiped out. "MicroEmissives is quite a big one and people will feel that it has gone, but there will be a lot of good smaller technology companies which will go missing without anyone noticing." Ritchie, a former board member of Scottish Enterprise, added: "It is a real shame that MicroEmissives is to go into administration. It is not a good time to be looking for emergency cash because it is just not around." The firm, listed on the Alternative Investment Market, suspended its shares following yesterday's announcement. The price before the suspension was 0.45p. A spin-out of Edinburgh and Napier universities, the company warned in September that if it did not find new financing it would run out of cash by mid-December. Last month it reported a loss of £3.8 million for the six months to 30 June – an increase of £700,000 over the first half of 2007. The news is the latest in a string of blows for Scotland's technology sector. Fellow university spin-out Wolfson is battling with a plunging share price and the departure of its chief executive Dave Shrigley, as well as the loss of most of its business with iPod maker Apple. Earlier this year, listed biotech firm Ardana and dental technology company Idmos both fell into administration after a period of poor trading, while in February, Stem Cell Sciences said it was closing its headquarters in the Scottish capital in favour of its facilities in Cambridge. Adrian Smith, programme director with the Edinburgh Pre-Incubator Scheme at the University of Edinburgh, added: "I understand they have always had a problem shifting product. It's a shame because there are a lot of able people there and with a bit of luck they'll come through it, something will happen. It's discouraging for other people if they see companies having a hard time on a public market." A spokesman for MicroEmissives said the company would issue another statement once an administrator was appointed.
wild bill
lol - I guess he'll get nothing - there's no cash left...
I wonder how much Kazuhisa Okamura will get paid for 2 days
wild bill
Chat Pages: 34  33  32  31  30  29  28  27  26  25  24  23  Older
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190122 23:33:06